The role of DNA methylation in the pathophysiology and treatment of bipolar 
disorder

Fries, Gabriel R.; Li, Qiongzhen; McAlpin, Blake; Rein, Theo; Walss-Bass, Consuelo; Soares, Jair C.; Quevedo, Joao

doi:10.1016/j.neubiorev.2016.06.010

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Journal Article

The role of DNA methylation in the pathophysiology and treatment of bipolar disorder

MPS-Authors

/persons/resource/persons80489

Rein, Theo
Dept. Translational Research in Psychiatry, Max Planck Institute of Psychiatry, Max Planck Society;

External Resource

No external resources are shared

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

There are no public fulltexts stored in PuRe

Supplementary Material (public)

There is no public supplementary material available

Citation

Fries, G. R., Li, Q., McAlpin, B., Rein, T., Walss-Bass, C., Soares, J. C., et al. (2016). The role of DNA methylation in the pathophysiology and treatment of bipolar disorder. NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 68, 474-488. doi:10.1016/j.neubiorev.2016.06.010.

Cite as: https://hdl.handle.net/11858/00-001M-0000-002C-56F3-6

Abstract

Bipolar disorder (BD) is a multifactorial illness thought to result from an interaction between genetic susceptibility and environmental stimuli. Epigenetic mechanisms, including DNA methylation, can modulate gene expression in response to the environment, and therefore might account for part of the heritability reported for BD. This paper aims to review evidence of the potential role of DNA methylation in the pathophysiology and treatment of BD. In summary, several studies suggest that alterations in DNA methylation may play an important role in the dysregulation of gene expression in BD, and some actually suggest their potential use as biomarkers to improve diagnosis, prognosis, and assessment of response to treatment. This is also supported by reports of alterations in the levels of DNA methyltransferases in patients and in the mechanism of action of classical mood stabilizers. In this sense, targeting specific alterations in DNA methylation represents exciting new treatment possibilities for BD, and the 'plastic' characteristic of DNA methylation accounts for a promising possibility of restoring environment-induced modifications in patients. (C) 2016 Elsevier Ltd. All rights reserved.